Adezmapimod (SB203580)

Catalog No.S1076 Synonyms: RWJ 64809, PB 203580

For research use only.

Adezmapimod (SB203580, RWJ 64809, PB 203580) is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM. SB203580 induces mitophagy and autophagy.

Adezmapimod (SB203580) Chemical Structure

CAS No. 152121-47-6

Selleck's Adezmapimod (SB203580) has been cited by 782 publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Other p38 MAPK Products

Biological Activity

Description Adezmapimod (SB203580, RWJ 64809, PB 203580) is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM. SB203580 induces mitophagy and autophagy.
Features First reported p38 inhibitor.
Targets
p38 MAPK [1]
(THP-1 cells)
PKB [1]
(THP-1 cells)
0.3 μM-0.5 μM 3 μM-5 μM
In vitro

SB203580 inhibits the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50 of 3–5 μm. SB203580 also inhibits IL-2-induced p70S6 kinase activation, although the concentration required is slightly higher with an IC50 above 10 μm. SB203580 also inhibits the activity of PDK1 in a dose-dependent manner with an IC50 in the 3–10 μm range. [1] SB203580 inhibits p38-MAPK stimulation of MAPKAPK2 with an IC50 of approximately 0.07 μM, whereas inhibits total SAPK/JNK activity with an IC50 of 3–10 μM. SB203580 at higher concentrations activates the ERK pathway, which subsequently enhances NF-κB transcriptional activity. [2] SB203580 induces autophagy in human hepatocellular carcinoma (HCC) cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 M3v1bmtqdmG|ZTDBd5NigQ>? M{LkWlExKM7:TR?= MnmxNVUhdWmw NWjEWXk3UW6qaXLpeJMheDN6IF3BVEBscW6jc3Wge4l1cCCLQ{WwJI9nKDBwNjFOwG0> NXnlUmIyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxN{e1NFU4Pyd-N{e1NFU4PzxxYU6=
THP-1 NIDUT2dHfW6ldHnvckBCe3OjeR?= NUfaPVdXUW6qaXLpeJMhVFCVLXnu[JVk\WRiVF7GZYxxcGFicILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOC5zNjFOwG0> NHXJVHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOyOVc3QCd-MUizNlU4Pjh:L3G+
PBMC MUTGeY5kfGmxbjDBd5NigQ>? NILwSGcyPSCvaX6= MoXESG1UVw>? M3fRfmlvcGmkaYTzJJRp\SC{ZXzlZZNmKG:oIHnueIVzdGW3a3nuMVEu[mW2YTD3bZRpKEmFNUCgc4YhOC5yM{eg{txO NEnTXGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkO2NVM6Pid-MUKzOlE{QTZ:L3G+
SW1353 M163PGZ2dmO2aX;uJGF{e2G7 MkHjNUBp MlzaSG1UVw>? NHr5SXRKdmirYnn0d{BKVC14IIDyc4R2[3Srb36ge4l1cCCLQ{WwJI9nKDBwMEWg{txO NHjiNIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUG0NFc1OSd-MUGxOFA4PDF:L3G+
Hela MkHoSpVv[3Srb36gRZN{[Xl? NIH2VGRFVVOR MkfOTY5pcWKrdIOgWIF1NWmwZIXj[YQhUEmYMTDMWHIhfHKjboPhZ5RqfmG2aX;uJIlvKGi3bXHuJGhmVGFiY3XscJMhf2m2aDDJR|UxKG:oIECuNUDPxE1? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl{NkexNUc,OTh7Mk[3NVE9N2F-
PC12 M{TBRWZ2dmO2aX;uJGF{e2G7 NV\B[IROOTBizszN M3XqOmROW09? NFXuUlFC[3SrdnH0[ZMhVnKoMj;BVmUhcW5icnH0JHBEOTJiY3XscJMh[XO|ZYPz[YQh[XNiSF:tNUBxem:2ZXnuJIlv\HWldHnvci=> NFvGd4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO0OVY5PSd-MkGzOFU3QDV:L3G+
RAW 264.7 NEWwU21EgXSxdH;4bYMhSXO|YYm= NWDvcoN1OTJwNTFOwG0> NEP2U|IyOmh? NHfIS4xFVVOR MWfCcI9kc3NibHX0bIFtKHSxeHnuMY1m\GmjdHXkJIN6fG:2b4jpZ4l1gQ>? M2LMTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEi1OVA1Lz5zN{S4OVUxPDxxYU6=
HCA2 MlnmSpVv[3Srb36gRZN{[Xl? NEnkTYozNjVizszN NX3WRndKUW6qaXLpeJMheDN6IH3l[IlifGWmIF3LNkBi[3SrdnH0bY9v NGXLZnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m2OFc5OCd-MUe5OlQ4QDB:L3G+
U937 NEDqbnJHfW6ldHnvckBCe3OjeR?= MlH1TY5pcWKrdIOgTmFMNW2nZHnheIVlKGmwdHXy[oVzd25vZ3HtcYEw[W6rc3;tfYNqdi2rbnT1Z4VlKFO2YYSxJJBpd3OyaH;yfYxifGmxbh?= NFX0e4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEG1O|EzOid-MUixOVcyOjJ:L3G+
U937 M{XGZ2Z2dmO2aX;uJGF{e2G7 MVLJcohq[mm2czDKRWsudWWmaXH0[YQhcW62ZYLm[ZJwdi2pYX3tZU9idmm|b335Z4lvNWmwZIXj[YQheDN6IIDoc5NxcG:{eXzheIlwdg>? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDF3N{GyNkc,OThzNUexNlI9N2F-
hESCs M2\POGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojlOUDPxE1? M3qwS2ROW09? NVrTbmVQUW6mdXPld{Bk[XKmaX;tfY9o\W6rYzDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cA>? NEizW3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[wNlM6QSd-MkO2NFI{QTl:L3G+
RAW264.7 MonDSpVv[3Srb36gRZN{[Xl? Mn3PNVAh|ryP M2DCVmlv\HWlZYOgZY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDifUBqdmirYnn0bY5oKEmOLUJOtkBz\WynYYPl MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MUC3PEc,OjN5OUGwO|g9N2F-
RAW264.7 MlLrSpVv[3Srb36gRZN{[Xl? MVyxNEDPxE1? MVfJcoR2[2W|IHHueIlqdm[uYX3tZZRwenliYXP0bZZqfHliYomgbY5pcWKrdHnu[{BqVk:VIILlcIVie2V? M3\sSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{mxNFc5Lz5{M{e5NVA4QDxxYU6=
RAW264.7 NHr0WJdHfW6ldHnvckBCe3OjeR?= M4HXblExKM7:TR?= MYXJcoR2[2W|IHHueIlqdm[uYX3tZZRwenliYXP0bZZqfHliYomgbY5pcWKrdHnu[{BPVyC{ZXzlZZNm M3jOd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{mxNFc5Lz5{M{e5NVA4QDxxYU6=
RAW264.7 MkLJSpVv[3Srb36gRZN{[Xl? MkX3NVAh|ryP M2PjUmlvcGmkaYTzJGxRWy2rbnT1Z4VlKHB|ODDNRXBMKHCqb4PwbI9zgWyjdHnvci=> NWfrOHJuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVYxPTdpPkK0NFE3ODV5PD;hQi=>
IEC-18 MnPOSpVv[3Srb36gRZN{[Xl? NFixTlUyOCEQvF2= NHu4VZVKdmirYnn0d{BNWFNvaX7keYNm\CCyM{igUWFRUyCyaH;zdIhwenmuYYTpc44> NYjC[W9nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OVgyOTBpPkKzO|U5OTFyPD;hQi=>
Sf9 NYnIW4ZjTnWwY4Tpc44h[XO|YYm= Mn3tN|AhdWmwcx?= MUnJcohq[mm2aX;uJI9nKG[3bHytcIVv\3SqIF\MRWcuPkircz3USXYhfGGpZ3XkJIh2dWGwIGLJVFIh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iYYX0c5Bpd3OyaH;yfYxifGmxbjDwdoUucW6ldXLheIVlKG[xcjCzNEBucW6|IH\vcIxwf2WmIHL5JIlv[3WkYYTpc44hf2m2aDDBWHAh\m:{IEKgbJJ{KGK7IFHEVE1IdG9iYYPzZZktKEmFNUCgQUAxNjBzIN88UU4> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR3NU[1OEc,OjZ2NUW2OVQ9N2F-
sf21 NGrpUGZHfW6ldHnvckBie3OjeR?= M3LIUWJqdmSrbnegZYZncW6rdImgeI8hf2muZDD0fZBmKGi3bXHuJIJqd3SrbjDsZYJmdGynZDDwN|gh[WyyaHGgLFkhfG9iM{WyJJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5ic3[yNUBqdnOnY4SgZ4VtdHNiU2DSJIFv[Wy7c3nzMEBM\CB;IECuNFIyPyEQvF2u Mm\WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6M{S0N|EoRjJ6OEO0OFMyRC:jPh?=
PBMC M130RWZ2dmO2aX;uJIF{e2G7 NYO1TIVDUW6qaXLpeIlwdiCxZjDUUmYu[WyyaHGgdJJw\HWldHnvckBjgSCuaYDvdI9tgXOjY3PoZZJq\GVvc4TpcZVt[XSnZDDoeY1idiCyZYLpdIhmemGuIHLsc49lKG2xbn;ueYNt\WG{IHPlcIx{NCCLQ{WwJF0hOC5yMkWg{txONg>? NITOUmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97OEezO|MxLz57OEezO|MxRC:jPh?=
PBMC M3niOmZ2dmO2aX;uJIF{e2G7 MWDJcohq[mm2aX;uJI9nKEySUz3zeIlufWyjdHXkJHRJM06ILXHsdIh{KHC{b3T1Z5Rqd25iYomgbJVu[W5icHXybZBp\XKjbDDicI9w\CCvb37vcpVkdGWjcjDj[YxteyBqUFLNR5MqNCCLQ{WwJF0hOC5yMkWg{txONg>? NYrNU|hVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUe4OFA6Oyd-OUe4OFA6OzxxYU6=
PBMC MY\GeY5kfGmxbjDhd5NigQ>? MVPJcohq[mm2aX;uJI9nKHB|ODDNRXAhc2mwYYPlJJJmdGG2ZXSgWG5HNWGucHjhJJJmdGWjc3Wg[pJwdSCyZYLpdIhmemGuIHLsc49lKG2xbn;ueYNt\WG{IHPlcIx{KCiSQl3DLUwhUUN3MDC9JFAvODN5IN88UU4> MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjB4MUi3Okc,OTJyNkG4O|Y9N2F-
PBMC Mm\NSpVv[3Srb36gZZN{[Xl? MUHJcohq[mm2aX;uJI9nKEySUz3pcoR2[2WmIFnMNU1j\XSjIIDyc4R2[3Srb36gbY4hcHWvYX6gdIVzcXCqZYLhcEBjdG:xZDDtc45wdnWlbHXhdkBk\WyuczjQRm1EeyluIFnDOVAhRSByLkC0PEDPxE1w NVq0VppXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUe4OFA6Oyd-OUe4OFA6OzxxYU6=
SW1353 MnTuSpVv[3Srb36gZZN{[Xl? NVntdFVQS2:vcH;1coQhf2G|IHX2ZYx2[XSnZDDmc5IhcXS|IHHibYxqfHlidH:gbY5pcWKrdDDJUE03KHC{b3T1Z5Rqd25iaX6gV3cyOzV|IHPlcIx{KHS{ZXH0[YQhf2m2aDDjfZRwc2mwZYOgTWwuOSCjbnSgWG5HNCCLQ{WwJF0hOC5yNTFOwG0v NUnRNIE6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC5PVk1PjdpPkGwPVk6PDZ5PD;hQi=>
SW1353 NWLVfoZpTnWwY4Tpc44h[XO|YYm= NHnzS5FKdmirYnn0bY9vKG:oIGTOSkBidmRiSVytNUBqdmS3Y3XkJGlNNTZicILv[JVkfGmxbjDpckBpfW2jbjDjbI9v\HKxLYPhdoNwdWFiU2egNVM2OyClZXzsd{whUUN3MDC9JFAvODVizszNMi=> Mk\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB7OUm0OlgoRjFyOUm5OFY5RC:jPh?=
THP1 MYLGeY5kfGmxbjDhd5NigQ>? MljHTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBKVDFicILv[JVkfGmxbjDpckBpfW2jbjDUTHAyKGOnbHzzMEBKSzVyIE2gNE4xPSEQvF2u M{mzeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEe3N|Y{Lz5zOEC3O|M3OzxxYU6=
THP1 MX\GeY5kfGmxbjDhd5NigQ>? MV7Jcohq[mm2aX;uJI9nKEySUz3zeIlufWyjdHXkJHRPTmGucHjhJJBzd2S3Y4Tpc44hcW5iaIXtZY4hXEiSMTDj[YxteyxiSVO1NEA:KDBwMEWg{txONg>? NGjTW209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC3O|M3Oyd-MUiwO|c{PjN:L3G+
THP1 M1PzVmZ2dmO2aX;uJIF{e2G7 NHv4b4dKdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJJR2dW:{IH7lZ5Jwe2m|IH\hZ5Rwei2jbIDoZUApXE6ILXHsdIhiMSCycn;keYN1cW:wIHnuJHRJWC1zIHPlcIx{NCCHQ{WwJF0hOC5yNjFOwG0v M4W0OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MEi2OFg2Lz5zMkC4OlQ5PTxxYU6=
THP1 MoDrSpVv[3Srb36gZZN{[Xl? NGTuZ2tKdmirYnn0bY9vKG:oIIT1cY9zKG6nY4Lvd4l{KG[jY4TvdkBidHCqYTDy[Yxm[XOnIHL5JHRJWC1zIHPlcIx{NCCLQ{WwJF0hOC5yNzFOwG0v M1joSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFU2Lz5zNU[1PFg2PTxxYU6=
monocytic cell MWTGeY5kfGmxbjDhd5NigQ>? NXLWUm1VUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KFSQRj3hcJBp[SCycn;keYN1cW:wIIXzbY5oKGyrcH;wc4x6e2GlY3jhdoll\SC|dHnteYxifGWmIHj1cYFvKG2xbn;jfZRq[yClZXzsd{whUUN3MDC9JFAvODd{IN88UU4> NUfvXHZ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK3Nlk3OzdpPkGyO|I6PjN5PD;hQi=>
THP1 MUHGeY5kfGmxbjDhd5NigQ>? M1foRWlvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBNWFNvc4TpcZVt[XSnZDDUUmYu[WyyaHGgdJJw\HWldHnvckBqdiCqdX3hckBud26xY4n0bYMh[2WubIOgLHRJWC1zKTygTWM2OCB;IECuNFczKM7:TT6= NHzlVpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUGzPVc1QSd-MUWxN|k4PDl:L3G+
THP-1 NH\0ZlNHfW6ldHnvckBie3OjeR?= MVjJcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgcIlxd3CxbInzZYNkcGG{aXTlJJN1cW23bHH0[YQhXE6ILXHsdIhiKHC{b3T1Z5Rqd25iaX6gWGhRNTFiY3XscJMhMGi3bXHuJI1wdm:leYTpZ{Bk\WyuczmsJGlEPTBiPTCwMlA4OiEQvF2u NWjyb3U1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW4N|c{OTBpPkG1PFM4OzFyPD;hQi=>
THP1 M{nKfmZ2dmO2aX;uJIF{e2G7 NUX5bYtGUW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCWTl\hcJBp[SCycn;keYN1cW:wIHnuJHRJWDFiY3XscJMtKEmFNUCgQUAxNjB5MjFOwG0v M{O5OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{WwN|Y4Lz5zNke1NFM3PzxxYU6=
PBMC M3qxXmZ2dmO2aX;uJIF{e2G7 M{PvZmlvcGmkaYTpc44hd2Zic4ThdIh6dG:lb3PjZYwh\W62ZYLveI95cW5iQjjTSWIqKHO2aX31cIF1\WRidIXtc5IhdmWlcn;zbZMh\mGldH;yJIFteGijIDjUUmYu[WyyaHGpJJBzd2S3Y4Tpc44h[nliaIXtZY4heGW{aYDo[ZJidCCkbH;v[EBud26xboXjcIVieiClZXzsd{hRSk2FczmsJGlEPTBiPTCwMlE3KM7:TT6= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86Pzh2MEmzK|46Pzh2MEmzQE9iRg>?
PBMC MWjGeY5kfGmxbjDhd5NigQ>? NGDofo1Ed26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgcIlxd3CxbInzZYNkcGG{aXTlJIlv\HWlZXSgWG5HNWGucHjhJJJmdGWjc3Wge4F{KGSndHXycYlv\WRiaX6gbJVu[W5icHXybZBp\XKjbDDicI9w\CCvb37vcpVkdGWjcjDj[YxteyxiSVO1NEA:KDBwMUmg{txONg>? MkP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV2NUSyN|EoRjF3NEW0NlMyRC:jPh?=
Sf9 M2nUUGZ2dmO2aX;uJIF{e2G7 NYS4RYZLUW6qaXLpeIlwdiCxZjDmeYxtNWynbnf0bEBHVEGJLU\IbZMuXEWYIITh[4dm\CCqdX3hckBTUVB{IHX4dJJme3OnZDDpckBU\jliY3XscJMh[nliZnz1c5Jme2OnboSgdI9t[XKrenH0bY9vKGG|c3H5MEBKSzVyIE2gNE4zKM7:TT6= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR3NU[1OEc,OjZ2NUW2OVQ9N2F-
HEK293F NGfuOpdHfW6ldHnvckBie3OjeR?= NGDCR49KdmirYnn0bY9vKG:oIIPv[Il2dSCjcoPlcoF1\SCjY4TpeoF1\WRiTj30[ZJucW6jbDDHV3QufGGpZ3XkJGJzfWerYTDtZYxigWliTWDLNUBmgHC{ZYPz[YQhcW5iSFXLNlk{TiClZXzsd{B2e2mwZzDGRW0ueDN6dHnk[UBieyC|dXLzeJJifGViYomgTW1CWCCjc4PhfUwhUUN3MDC9JFAvOjJizszNMi=> M{OzO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUSxN|YzLz5{OUW0NVM3OjxxYU6=
HEK-293 MVzGeY5kfGmxbjDhd5NigQ>? M4TWW2lvcGmkaYTpc44hd2ZiUlnQNmshcW5iTVTQMZN1cW23bHH0[YQhUEWNLUK5N{Bk\WyuczDveoVzNWW6cILld5NqdmdiTl;ENkBie3Onc4Pl[EBieyCLTEigd4VkemW2aX;uMEBKSzVyIE2gNE4zPSEQvF2u M{e2ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUC5PFY4Lz5{N{GwPVg3PzxxYU6=
whole blood cell M2js[2Z2dmO2aX;uJIF{e2G7 MVmwMlAyKHSxIEGwNEB2VQ>? MUnJcohq[mm2aX;uJI9nKHB|OD3y[YxifGWmIFnMNU1j\XSjIILlcIVie2ViYomge4hwdGViYnzvc4Qh[2WubIOgZZQhOTBiZT20JJRwKDFyIHWtPEBONCCLQ{WwJF0hOC5|NTFOwG0v MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjh3Mke1OEc,OTJ6NUK3OVQ9N2F-
PBMC MUTGeY5kfGmxbjDhd5NigQ>? NFu5OmdKdmirYnn0bY9vKG:oIICzPEBOSVBia3nuZZNmKHKnbHH0[YQhXE6ILXHsdIhiKHKnbHXhd4Uh\nKxbTDw[ZJqeGincnHsJIJtd2:mIH3vco9vfWOuZXHyJINmdGy|IDjQRm1EMSxiSVO1NEA:KDBwNUmg{txONg>? NFfuUmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkC2NVg4Pid-MUKwOlE5PzZ:L3G+
PBMC NGjzS2tHfW6ldHnvckBie3OjeR?= MYLJcohq[mm2aX;uJI9nKHSqZTDy[Yxm[XOnIH;mJJR2dW:{IH7lZ5Jwe2m|IH\hZ5RweiCjbIDoZUBnem:vIIDldolxcGW{YXygZoxwd2RibX;uc452[2ynYYKgZ4VtdHNuIFnDOVAhRSByLkW5JO69VS5? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjN4MUO5Okc,OTJ|NkGzPVY9N2F-
PBMC M{XJcmZ2dmO2aX;uJIF{e2G7 MV;Jcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgWG5HNWGucHjhJJJmdGWjc3WgbY4hWEKPIHPlcIx{NCCLQ{WwJF0hOC53OTFOwG0v M1f3flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{OEWyO|U1Lz5zMki1Nlc2PDxxYU6=
whole blood cell NFr0ZWhHfW6ldHnvckBie3OjeR?= NWK2cplPOC5yMTD0c{AyODBidV2= M3LDeGlvcGmkaYTpc44hd2ZicEO4MZJmdGG2ZXSgWG5HNWGucHjhJJJmdGWjc3WgZpkhf2ixbHWgZoxwd2RiY3XscJMh[XRiMUCg[U01KHSxIEGwJIUuQCCPLDDJR|UxKD1iMD65OEDPxE1w NYPoUodORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK4OVI4PTRpPkGyPFUzPzV2PD;hQi=>
BMDC M2jsUGFvfGmrbn\sZY1u[XSxcomgZZN{[Xl? MVSxJIhz MmLvRY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBEPTeETD:2JI1wfXOnIFLNSGMh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBKVC14IIDyc4R2[3Srb36gdJJmcW6ldXLheIVlKG[xcjCxJIhzKHC{aX;yJJRwKEySUz3zeIlufWyjdHnvckBu\WG|dYLl[EBi\nSncjCxPEBpenNiYomgSWxKW0FuIFnDOVAhRSB|LkWg{txONg>? M2fl[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES3NlU6Lz5{NEC0O|I2QTxxYU6=
BMDC NEfxbWVCdnSraX7mcIFudWG2b4L5JIF{e2G7 M3vBWlEhcHJ? NFW5R5NCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKEN3N1LMM|YhdW:3c3WgRm1FSyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWy2rbnT1Z4VlKEmOLUGyJJA1OCCycn;keYN1cW:wIIDy[Ylv[3WkYYTl[EBnd3JiMTDodkBxemmxcjD0c{BNWFNvc4TpcZVt[XSrb36gcYVie3W{ZXSgZYZ1\XJiMUigbJJ{KGK7IFXMTXNCNCCLQ{WwJF0hPSEQvF2u M{nGTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES3NlU6Lz5{NEC0O|I2QTxxYU6=
HEK-293 MnG1SpVv[3Srb36gZZN{[Xl? MXjJcohq[mm2aX;uJI9nKFKLUELLJIlvKFCjbULDV2s1NXO2aX31cIF1\WRiSFXLMVI6OyClZXzsd{BwfmW{LXX4dJJme3OrbnegWGxTOiCjc4Pld5Nm\CCjczDJUFghe2WlcnX0bY9vNCCLQ{WwJF0hPi5|MTFOwG0v MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFyOUi2O{c,OjdzMEm4Olc9N2F-
BMDC Moq1RY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? NGPDZYUyKGi{ MnP1RY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBEPTeETD:2JI1wfXOnIFLNSGMh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBVVk[jbIDoZUBxem:mdXP0bY9vKHC{ZXnuZ5Vj[XSnZDDmc5IhOSCqcjDwdolweiC2bzDMVHMue3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhOThiaILzJIJ6KEWOSWPBMEBKSzVyIE2gO{42KM7:TT6= NWDnXI1rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFczPTlpPkK0NFQ4OjV7PD;hQi=>
macrophage-like cell MkniRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? NYTJeJJvOzBibXnudy=> Mm\mRY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBpfW2jbjDIUE03OCCmZYLpeoVlKG2jY4LvdIhi\2VvbHnr[UBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJHRPTmGucHjhJJBzd2S3Y4Tpc44hfHKnYYTl[EA{OCCvaX7zJIJm\m:{ZTDMVHMhe3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhOjRiaILzJIJ6KEWOSWPBMEBKSzVyIE2gPE43KM7:TT6= NVXa[mo{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NVExQDlpPkKzPFEyODh7PD;hQi=>
WS NIDvOFJHfW6ldHnvckBie3OjeR?= NVizOmxvOi53IIXN NEiyfndKdmirYnn0bY9vKG:oIHHubZNwdXmlaX6tbY5lfWOnZDDQN|gu[WyyaHGgZYN1cX[jdHnvckBqdiCqdX3hckBpfW2jbjDUSXJVNWmvbX;yeIFtcXOnZDDXV{Bk\WyuczDhd5Nme3OnZDDhd{BJW1B{NzDwbI9{eGixconsZZRqd25iYYSgNk42KHWP MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ3OUi3NUc,OTd4NUm4O|E9N2F-
WS MnjxSpVv[3Srb36gZZN{[Xl? MWfJcohq[mm2aX;uJI9nKE2NMjDt[YRq[XSnZDDIV3AzPyCyaH;zdIhwenmuYYTpc44hcW5iaX3tc5J1[Wyrc3XkJHdUKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDGMYFkfGmwIIP0doV{eyCoaXLy[ZM> NGnDNZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m2OFc5OCd-MUe5OlQ4QDB:L3G+
WS MmDiSpVv[3Srb36gZZN{[Xl? M3zWR2lvcGmkaYTpc44hd2ZicEO4JI1m\GmjdHXkJG1MOiCjY4TpeoF1cW:wIHnuJHdUKGOnbHzz M1yxSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OU[0O|gxLz5zN{m2OFc5ODxxYU6=
A673 M1[3[JFJXFNiYYPzZZk> M1yze5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| NHP0cGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 NEX4b5FyUFSVIHHzd4F6 MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| Mmr2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 M4DQb5FJXFNiYYPzZZk> NETlZWdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= NX7M[HRPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD MWrxTHRUKGG|c3H5 NY\McJM5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLEJINmdGy| NGjLeGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-12 NEPJTYpyUFSVIHHzd4F6 NE\a[VhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= M2PnOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 NH65cIJyUFSVIHHzd4F6 Mn;sdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= NEXOXZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 NIrWcJNyUFSVIHHzd4F6 MU\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= MoT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC M1rheZFJXFNiYYPzZZk> M4\ZcpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz MkDFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Assay
Methods Test Index PMID
Western blot phospho-p38 / p38 ; p-ASK1 / ASK1 / P-JNK / p-MKK4 / p-ERK ; phospho-MK2(T334) / phospho-HSP27(S82) / phospho-Akt(T308) / phospho-Akt(S473) 25747578 24082073 21737674
Immunofluorescence dsRNA / hnRNP A1 25747578
Growth inhibition assay Cell viability 23001390
In vivo SB203580 protects pig myocardium against ischemic injury in an in vivo model. [4]SB203580 is effective to prevent and treat the disease in MRL/lpr mice model of Systemic lupus erythematosus (SLE). [5]

Protocol (from reference)

Kinase Assay:

[1]

  • Cellular receptor kinase phosphorylation assay :

    4 μg of sheep anti-PKBα is immobilized on 25 μL of protein G-Sepharose overnight (or 1.5 hours) and washed in Buffer A (50 mm Tris, pH 7.5, 1 mm EDTA, 1 mm EGTA, 0.5 mm Na3VO4, 0.1% β-mercaptoethanol, 1% Triton X-100, 50 mm sodium fluoride, 5 mm sodium pyrophosphate, 0.1 mm phenylmethylsulfonyl fluoride, 1 μg/mL aprotinin, pepstatin, leupeptin, and 1 μm microcystin). The immobilized anti-PKB is then incubated with 0.5 ml of lysate (from 5 × 106 cells) for 1.5 hours and washed three times in 0.5 mL of Buffer A supplemented with 0.5 m NaCl, two times in 0.5 mL of Buffer B (50 mm Tris-HCl, pH 7.5, 0.03% (w/v) Brij-35, 0.1 mm EGTA, and 0.1% β-mercaptoethanol), and twice with 100 μl of assay dilution buffer; 5× assay dilution buffer is 100 mm MOPS, pH 7.2, 125 mm β-glycerophosphate, 25 mm EGTA, 5 mm sodium orthovanadate, 5 mm DTT. To the PKB enzyme immune complex is added 10 μL of assay dilution buffer, 40 μm protein kinase A inhibitor peptide, 100 μm PKB-specific substrate peptide, and 10 μCi of [γ-32P]ATP, all made up in assay dilution buffer. The reaction is incubated for 20 minutes at room temperature with shaking, then samples are pulse spun, and 40 μL of reaction volume are removed into another tube to which is added 20 μL of 40% trichloroacetic acid to stop the reaction. This is mixed and incubated for 5 minutes at room temperature, and 40 μL is transferred onto P81 phosphocellulose paper and allowed to bind for 30 seconds. The P81 piece is washed three times in 0.75% phosphoric acid then in acetone at room temperature. γ-32P incorporation is then measured by scintillation counting.

Cell Research:

[1]

  • Cell lines: CT6 cell , BA/F3 F7 cell
  • Concentrations: 0–30 μM
  • Incubation Time: 1 hour
  • Method:

    CT6 cell and BA/F3 F7 cell are rested by washing three times in RPMI and culturing overnight in RPMI, 5% fetal calf serum in the absence of growth factor, antibiotics, or β-mercaptoethanol supplements. 2–5 × 106 rested CT6 cells are resuspended in 2 mL of RPMI, 5% fetal calf serum and preincubated with SB203580 or vehicle control as indicated in figure legends. Cells are then stimulated with 20 ng/ml recombinant human IL-2 for 5 minutes at 37  °C and pelleted in a minifuge for 30 seconds, medium is aspirated, and the pellet is lysed in the appropriate buffer. BA/F3 cells stably expressing deletion mutants of IL-2 receptor β chain are maintained in glutamine containing RPMI further supplemented with 5% fetal calf serum and 0.2 μg/mL G418. The cells are then washed extensively, rested overnight, and washed again before activating with IL-2; such cell preparations are >90% T cells. Cellular proliferation assays are performed by measurement of [3H]thymidine incorporation.

Animal Research:

[5]

  • Animal Models: Systemic lupus erythematosus (SLE) are established in female MRL/lpr mice and female C57BL/6 mice
  • Dosages: 0.1 M/day
  • Administration: Orally administered

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.

5mg/mL

Chemical Information

Molecular Weight 377.43
Formula

C21H16FN3OS

CAS No. 152121-47-6
Storage 3 years -20°C(in the dark) powder
Smiles CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Adezmapimod (SB203580) | Adezmapimod (SB203580) supplier | purchase Adezmapimod (SB203580) | Adezmapimod (SB203580) cost | Adezmapimod (SB203580) manufacturer | order Adezmapimod (SB203580) | Adezmapimod (SB203580) distributor